Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
Genentech (NYSE: DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Facebook (FB) Shares Dip Below All-Important $38 Level
- Wal-Mart Stores (WMT) Reports Solid Q1, Comps Up 2.6%; Offers Q2 Outlook
Create E-mail Alert Related Categories
FDA, Hot ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
